Table 1.
Demographic and pathological characteristics of participants by diagnostic group
| bvAD | tAD | bvFTD | Controls | p-value† | |
|---|---|---|---|---|---|
| N | 9 | 6 | 18 | 13 | |
| Age at death | 70.1 (9.0) | 79.7 (12.7) | 64.8 (8.8) | 66.8 (11.4) | 0.68 |
| Sex, no. of females, % | 5, 55.6 | 2, 33.3 | 10, 55.6 | 6, 50.0 | 0.78 |
| Thal stage, mean | 5.0 (0.0) | 4.8 (0.4) | 0.61 (0.89) | 1.67 (1.43) | bvAD>CN, p < 0.001, tAD>CN, p < 0.001, bvAD>bvFTD, p < 0.001, tAD>bvFTD, p < 0.001 |
| Braak stage, mean | 5.6 (0.5) | 5.6 (0.5) | 1.11 (1.20) | 0.67 (0.75) | bvAD>CN, p < 0.001, tAD>CN, p < 0.001, tAD>bvFTD, p < 0.001 |
| LBD◊ present in amygdala or brainstem, % | 44.4 | 50 | n/a | n/a | |
| LATE□ present, % | 11.1 | 50 | n/a | n/a |
†Significant differences in age were assessed by an ANOVA test and differences in sex were assessed with a χ2 test, differences in Thal and Braak stages were assessed with emmeans post hoc tests in R version 4.0.2 [35]
◊LBD = Lewy body disease, assessed as present or absent
□LATE = Limbic predominant age related TDP-43 pathology, assessed as present or absent
bvAD behavioral variant of Alzheimer’s disease, tAD typical AD, bvFTD behavioral variant frontotemporal dementia